BioSpace News Archive

Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Oppenheimer MedTech, Tools & Diagnostic Summit

Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has appointed pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Melissa Gonzales has been named president of its Women’s Health business.

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced data on the differentiated activity profile of balstilimab, an anti-PD-1 antibody, and new Phase 1 clinical data for AGEN2373

The vendor landscape of the global market of hematology diagnostics features a handful of companies collectively accounting for a large share in the overall market, hinting at a largely consolidated vendor landscape, observes Transparency Market Research in a recent report.

The global endoscopic ultrasound needles market was valued at around US$ 139.2 Mn in 2016 is anticipated to expand at a stable CAGR of over 4.5% during forecast period of 2017 to 2025, according to a new report published by Transparency Market Research titled ’Endoscopic Ultrasound Needles Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025.’

Coronary Artery Bypass Graft is most common type of heart surgery that is performed to treat people suffering from severe angina and coronary artery heart disease.

Development of novel extended oral antibiotics and molecules to treat antibiotic-resistant prosthetic infections is forecast to elevate market growth.

CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced that their abstract with first interim data from the phase I clinical trial investigation CTL-002 as monotherapy and in combination with a checkpoint inhibitor has been selected by ASCO for a poster presentation.

GammaDelta Therapeutics, a company focussed on exploiting the unique properties of gamma delta T cells for immunotherapy, announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the Company’s allogeneic variable delta 1 gamma-delta T cell therapy, GDX012, to be investigated as a treatment for haematological malignancies.